Table 5. Factors associated with Cr reduction after use of terlipressin was stopped.
| Variables | Cr reduction (n=13) | No Cr reduction (n=20) | P value |
|---|---|---|---|
| Age (years) | 58±7.5 | 55.7±11.6 | 0.494 |
| Ascites | 8 (61.5%) | 13 (65.0%) | 0.84 |
| Hepatic encephalopathy | 2 (15.4%) | 0 | 0.07 |
| Hepatocellular carcinoma | 3 (23.1%) | 2 (10.0%) | 0.306 |
| Sex (male/female) | 9 (69.2%)/4 (30.8%) | 13 (65.0%) /7 (35.0%) | 0.801 |
| Child-Pugh score | 8.3±2.8 | 7.3±1.8 | 0.36 |
| MELD score | 5.8±3.6 | 3.9±2 | 0.062 |
| Hemoglobin (g/L) | 77.3±26.7 | 81±23.8 | 0.531 |
| White blood cell (109/L) | 7.9±4.1 | 6.1±3.5 | 0.101 |
| Red blood cell (1012/L) | 2.6±0.9 | 3.1±0.9 | 0.151 |
| Neutrophil (109/L) | 6±3.4 | 4.4±2.7 | 0.117 |
| Lymphocyte (109/L) | 1.3±0.9 | 1.2±0.9 | 0.698 |
| Platelet (109/L) | 132.2±119.8 | 102.2±80.8 | 0.519 |
| Total bilirubin (μmol/L) | 34.9±38 | 23.8±16.1 | 0.754 |
| Direct bilirubin (μmol/L) | 21.8±25.1 | 12.4±13.1 | 0.376 |
| Alanine transaminase (U/L) | 30.7±23.7 | 28.1±30 | 0.606 |
| AST (U/L) | 42.2±32,2 | 47.2±82.9 | 0.357 |
| Albumin (g/L) | 28.9±5.1 | 29.5±7.5 | 0.58 |
| Prothrombin time (s) | 19.5±5.1 | 17.4±3 | 0.179 |
| Activated partial thromboplastin time (s) | 43.4±10.3 | 39.7±5.8 | 0.185 |
| International normalized ratio | 1.7±0.6 | 1.4±0.3 | 0.173 |
| Cr (μmol/L) | 80.9±26.9 | 61±15.4 | 0.011 |
| CysC (mg/L) | 1.5±1.1 | 0.9±0.3 | 0.197 |
| Serum sodium (mmol/L) | 136.3±5.3 | 138.1±3.4 | 0.253 |
| Cumulative defined daily dose (mg) | 1.1±0.8 | 0.9±0.5 | 0.897 |
| Total dose of terlipressin (mg) | 13.7±9.9 | 11.3±5.6 | 0.897 |
| Duration of terlipressin (days) | 3.8±2.3 | 3.1±1.4 | 0.224 |
MELD, model of end stage liver disease; Cr, creatinine; CysC, cystatin C; AST, aspartate transaminase.